Cash PositionThe company ended Q1 with $7 million in cash and no debt, raising approximately $5 million selling stock, believed to have enough cash into 2026.
Market PotentialThe company is aiming for wide commercial opportunities across medical and non-medical industries for silicon nitride, indicating a large market potential.
Valuation And RatingThe current valuation is attractive, maintaining a BUY rating with a price target adjusted to $28, representing significant upside from the current share price.